Robert Eckert - Amgen Independent Director
AMGN Stock | MXN 4,450 6.50 0.15% |
Director
Mr. Robert A. Eckert is the Lead Independent Director of the Company. Robert A. Eckert was an Operating Partner at Friedman Fleischer Lowe, a private equity firm, since September 2014. Mr. Eckert was the Chief Executive Officer of Mattel, Inc., a toy design, manufacture and marketing company, having held this position from 2000 through December 2011, and its Chairman of the Board from 2000 through 2012. He was President and Chief Executive Officer of Kraft Foods Inc., a consumer packaged food and beverage company, from 1997 to 2000, Group Vice President from 1995 to 1997, President of the Oscar Mayer Foods Division from 1993 to 1995 and held various other senior executive and other positions from 1977 to 1992. Mr. Eckert was a director of McDonalds Corporationrationration, a company which franchises and operates McDonalds restaurants in the global restaurant industry, since 2003, serving as the Chair of the Compensation Committee and a member of the Executive and Governance Committees. Mr. Eckert was a director of Smart Final Stores, Inc., a warehouse store, from May 2013 until July 2014 prior to it becoming a publiclytraded company. Mr. Eckert also has served as a director of Levi Strauss Co., a privatelyheld jeans and casual wear manufacturer, since 2010. He was appointed director of Eyemart Express Holdings LLC, a privatelyheld eyewear retailer and portfolio company of Friedman Fleischer Lowe, in 2015. Mr. Eckert is on the Global Advisory Board of the Kellogg School of Management at Northwestern University and serves on the Eller College National Board of Advisors at the University of Arizona since 2016.
Age | 63 |
Tenure | 8 years |
Phone | 805 447 1000 |
Web | https://www.amgen.com |
Amgen Management Efficiency
The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Richard Vinroot | Martin Marietta Materials | 74 | |
Mayo Shattuck | Capital One Financial | 63 | |
Richard Brissenden | McEwen Mining | 70 | |
Pamela Joyner | First Republic Bank | 58 | |
Stephen Zelnak | Martin Marietta Materials | 73 | |
William McDonald | Martin Marietta Materials | 72 | |
Richard Rexach | Verizon Communications | 63 | |
Kathryn Tesija | Verizon Communications | 54 | |
Smith Davis | Martin Marietta Materials | 70 | |
Frank Byrne | Steel Dynamics | 64 | |
Martin Gibbs | First Republic Bank | 79 | |
Francois LocohDonou | Capital One Financial | 46 | |
Aparna Chennapragada | Capital One Financial | 41 | |
John Koraleski | Martin Marietta Materials | 66 | |
James Marcuccilli | Steel Dynamics | 66 | |
Jody Lindell | First Republic Bank | 65 | |
Bradford Warner | Capital One Financial | 66 | |
Donald Slager | Martin Marietta Materials | 56 | |
Pierre Leroy | Capital One Financial | 69 | |
John Bates | Steel Dynamics | 71 | |
Frank Menaker | Martin Marietta Materials | 74 |
Management Performance
Return On Equity | 1.26 | |||
Return On Asset | 0.0997 |
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Linda Louie, VP Officer | ||
Frank Herringer, Independent Director | ||
Nancy Grygiel, Sr Officer | ||
Francois Carbonnel, Independent Director | ||
Rebecca Henderson, Independent Director | ||
Annette Such, Chief Accounting Officer | ||
Sanders Williams, Independent Director | ||
Vance Coffman, Lead Independent Director | ||
David Reese, Executive Vice President - Research and Development | ||
Tyler Jacks, Independent Director | ||
Brian McNamee, Executive Vice President - Full Potential Initiatives | ||
Gregory Garland, Independent Director | ||
Charles Holley, Director | ||
Esteban Santos, Executive Vice President Operations | ||
Jonathan Graham, Senior Vice President General Counsel, Secretary | ||
Sean Harper, Executive Vice President - Research and Development | ||
Mike Zahigian, VP Officer | ||
Ellen Kullman, Director | ||
Frank Biondi, Independent Director | ||
Arvind Sood, IR Contact Officer | ||
David Meline, CFO and Executive VP | ||
Ronald Sugar, Independent Director | ||
Stuart Tross, Senior Vice President - Human Resources | ||
Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | ||
Murdo Gordon, Executive Vice President of Global Commercial Operations | ||
Peter Griffith, Ex CFO | ||
Wanda Austin, Independent Director | ||
Robert Eckert, Independent Director | ||
Madhavan Balachandran, Executive VP of Operations | ||
Lori Johnston, Senior Vice President - Human Resources | ||
Brian Druker, Independent Director | ||
Cynthia Patton, Senior Vice President Chief Compliance Officer | ||
Greg Garland, Independent Director | ||
Robert Williams, Independent Director | ||
Judith Pelham, Independent Director | ||
David Baltimore, Independent Director | ||
Fred Hassan, Director | ||
David Piacquad, Senior Vice President - Business Development | ||
Anthony Hooper, Executive VP of Global Commercial Operations | ||
David MD, Ex RD |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 1.26 | |||
Return On Asset | 0.0997 | |||
Profit Margin | 0.25 % | |||
Operating Margin | 0.38 % | |||
Current Valuation | 3.36 T | |||
Shares Outstanding | 533.98 M | |||
Shares Owned By Insiders | 0.20 % | |||
Shares Owned By Institutions | 80.38 % | |||
Price To Earning | 267.53 X | |||
Price To Book | 40.33 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amgen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amgen's short interest history, or implied volatility extrapolated from Amgen options trading.
Pair Trading with Amgen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.Moving together with Amgen Stock
0.66 | ROGN | Roche Holding AG | PairCorr |
Moving against Amgen Stock
0.65 | AXTELCPO | Axtel SAB de Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Amgen Stock analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |